Application of intraoperative frozen section examination in the management of female breast cancer in China: a nationwide, multicenter 10-year epidemiological study

World Journal of Surgical Oncology

You-Lin Qiao¹  Shan Zheng⁷  Xiao-Ming Xie⁹  Jin-Hu Fan¹  Bao-Ning Zhang²  Jing Li¹  Qing-Kun Song¹  Lin Zhao³  Feng Xu⁴  Ya-Nan Kong⁹  Wei-Liang Feng⁵  Jian-Jun He⁸  Rong Huang⁶  Yu Ren⁸  Ke Wang⁸ 

[1] Department of Cancer Epidemiology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, P.R. China;Center of Breast Disease, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, P.R. China;Department of Breast Surgery, Liaoning Cancer Hospital, No. 44 Xiaoyanhe Road, Dadong District, Shenyang 110041, P.R. China;Department of Breast-thyroid Surgery, Xiangya Second Hospital, Central South University, No. 139 Renminzhonglu, Changsha 410011, P.R. China;Department of Breast Surgery, Zhejiang Cancer Hospital, No. 38 Banshanqiao Guanji Road, Hangzhou 310022, P.R. China;Department of Epidemiology, West China School of Public Health, Sichuan University, Chengdu, Sichuan 610041, P.R. China;Department of Pathology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, P.R. China;Department of Oncosurgery, the First Affiliated Hospital of Medical College, Xi’an Jiaotong Universtiy, 277 Yanta West Road, Xi’an 710061, P.R. China;Department of Breast Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East, Guangzhou 510060, P.R. China

关键词: Sociodemographic factor;    Intraoperative frozen section examination;    Female breast cancer;    Application mode;   

Others  :  1148590
DOI  :  10.1186/1477-7819-12-225

 received in 2013-11-16, accepted in 2014-07-04,  发布年份 2014

【 摘 要 】

Background

Intraoperative frozen section examination (IFSE) during breast cancer surgery can partly reflect the status of surgical treatment since the surgical method used directly determines the purpose of IFSE use in disease management. This study aims to investigate the application of, changing trends in, and factors influencing IFSE in the management of female breast cancer in China.

Methods

We collected the sociodemographic and clinical data of 4,211 breast cancer patients between 1999 and 2008 and statistically analyzed these data using χ² or Fisher’s exact tests.

Results

A total of 2,283 (54.22%) patients with breast cancer underwent IFSE. During the 10-year study period, IFSE use was associated with an increase in the number of sentinel lymph node biopsies (SLNB) and breast-conserving surgeries (BS) performed, with significant regional differences noted in this trend (P <0.05). Patients’ education, occupation, age, tumor size estimated by preoperative palpation, and the use of imaging examinations affected the purpose of IFSE use (P <0.05).

Conclusions

Our results show that the purpose of IFSE in the surgical treatment of breast cancer in China is gradually approaching that in developed countries. We believe that policymakers must address the differences in breast cancer treatment based on the socioeconomic status of patients. Lastly, the use of IFSE for determining tumor characteristics should be avoided as far as possible, and patient education and breast cancer screening programs tailored to the Chinese population should be established. Our findings may guide the formulation of breast cancer control strategies in China and other low-income countries.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Sparkman RS: Reliability of frozen sections in the diagnosis of breast lesions. Ann Surg 1962, 155:924-934.
• [2]Bloodgood JC: When cancer becomes a microscopic disease, there must be tissue diagnosis in the operating room. JAMA 1927, 88(13):1022-1023.
• [3]Dankwa EK, Davies JD: Frozen section diagnosis: an audit. J Clin Pathol 1985, 38(11):1235-1240.
• [4]Laucirica R: Intraoperative assessment of the breast: guidelines and potential pitfalls. Arch Pathol Lab Med 2005, 129(12):1565-1574.
• [5]Ghaemmaghami F, Behnamfar F, Ensani F: Intraoperative frozen sections for assessment of female cancers. Asian Pac J Cancer Prev 2007, 8(4):635-639.
• [6]Jaafar H: Intra-operative frozen section consultation: concepts, applications and limitations. Malays J Med Sci 2006, 13(1):4-12.
• [7]Yang L, Parkin DM, Ferlay J, Li L, Chen Y: Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005, 14(1):243-250.
• [8]Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL, Zheng S, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, Li JY, He JJ, Qiao YL: A nation-wide multicenter 10-year (1999–2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer 2011, 11:364.
• [9]Zheng S, Bai JQ, Li J, Fan JH, Pang Y, Song QK, Huang R, Yang HJ, Xu F, Lu N, Qiao YL: The pathologic characteristics of breast cancer in China and its shift during 1999–2008: a national-wide multicenter cross-sectional image over 10 years. Int J Cancer 2012, 131(11):2622-2631.
• [10]Scarff RW, Torloni H: Histological Typing of Breast Tumours. 2nd edition. Geneva: World Health Organization; 1981:15-26.
• [11]Tavassoli FA, Devilee P: Pathology and Genetics of Tumours of the Breast and Female Genital Organs, Volume 4. Lyon: IARC, World Health Organization; 2003:221-232.
• [12]American Joint Committee on Cancer: AJCC cancer staging manual. 5th edition. Philadelphia: Lippincott-Raven; 1997:171-180.
• [13]American Joint Committee on Cancer: AJCC cancer staging manual. 6th edition. New York: Springer; 2002:223-240.
• [14]Wang Q, Li J, Zheng S, Li JY, Pang Y, Huang R, Zhang BN, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, He JJ, Fan JH, Qiao YL: Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China. BMC Cancer 2012, 12:122.
• [15]Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, Sandelin K, Derossis A, Cody H, Foulkes WD: Is breast cancer the same disease in Asian and Western countries? World J Surg 2010, 34(10):2308-2324.
• [16]Giuliano AE: Sentinel node biopsy: standard of care. Breast J 2003, 9(s1):S3-S6.
• [17]Edge SB, Niland JC, Bookman MA, Theriault RL, Ottesen R, Lepisto E, Weeks JC: Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 2003, 95(20):1514-1521.
• [18]Goyal A, Mansel RE: Recent advances in sentinel lymph node biopsy for breast cancer. Curr Opin Oncol 2008, 20(6):621-626.
• [19]Burak WE Jr, Agnese DM, Povoski SP: Advances in the surgical management of early stage invasive breast cancer. Curr Probl Surg 2004, 41(11):882-935.
• [20]Povoski SP, Jimenez RE, Wang WP, Xu RX: Standardized and reproducible methodology for the comprehensive and systematic assessment of surgical resection margins during breast-conserving surgery for invasive breast cancer. BMC Cancer 2009, 9:254.
• [21]Zhang BN: Progress in surgical treatment of early stage breast cancer. J Practical Oncol 2002, 17(6):367-369.
• [22]Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002, 347(16):1233-1241.
• [23]Blichert-Toft M, Nielsen M, During M, Moller S, Rank F, Overgaard M, Mouridsen HT: Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 2008, 47(4):672-681.
• [24]Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, Kissin M, Mansel RE: Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006, 95(3):279-293.
• [25]Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, De Lucia F, Gennari R: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003, 349(6):546-553.
• [26]Julian TB, Krag D, Brown A, Anderson S, Harlow S, Ashikaga T, Weaver D, Miller B, Jalovec L, Frazier T: Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Breast Cancer Res Treat 2004, 88(Suppl 1):S11-S12.
• [27]Gnant M, Harbeck N, Thomssen C: St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel) 2011, 6(2):136-141.
• [28]Edge SB, Ottesen RA, Lepisto EM, Niland JC, Theriault RL, Bookman MA, Weeks JC: Surgical biopsy to diagnose breast cancer adversely affects outcomes of breast cancer care: finding from the National Comprehensive Cancer Network. Breast Cancer Res Treatmen 2005, 94(Suppl 1):S9. Abstract #12
• [29]Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready DR, Mamounas EP, Costantino JP, Wolmark N, National Surgical Adjuvant Breast and Bowel Project: Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007, 8(10):881-888.
• [30]Smith GL, Xu Y, Shih YC, Giordano SH, Smith BD, Hunt KK, Strom EA, Perkins GH, Hortobagyi GN, Buchholz TA: Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. J Am Coll Surg 2009, 209(4):425-433.
• [31]Farrow DC, Hunt WC, Samet JM: Geographic variation in the treatment of localized breast cancer. N Engl J Med 1992, 326(17):1097-1101.
• [32]Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS: Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med 1992, 326(17):1102-1107.
• [33]Richardson JL, Langholz B, Bernstein L, Burciaga C, Danley K, Ross RK: Stage and delay in breast cancer diagnosis by race, socioeconomic status, age and year. Br J Cancer 1992, 65(6):922-926.
• [34]Bish A, Ramirez A, Burgess C, Hunter M: Understanding why women delay in seeking help for breast cancer symptoms. J Psychosom Res 2005, 58(4):321-326.
• [35]Grunfeld EA, Ramirez AJ, Hunter MS, Richards MA: Women’s knowledge and beliefs regarding breast cancer. Br J Cancer 2002, 86(9):1373-1378.
• [36]Keating NL, Weeks JC, Borbas C, Guadagnoli E: Treatment of early stage breast cancer: do surgeons and patients agree regarding whether treatment alternatives were discussed? Breast Cancer Res Treat 2003, 79(2):225-231.
• [37]Gilligan MA, Kneusel RT, Hoffmann RG, Greer AL, Nattinger AB: Persistent differences in sociodemographic determinants of breast conserving treatment despite overall increased adoption. Med Care 2002, 40(3):181-189.
• [38]Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J, Edge S, Guadagnoli E, Lynch JJ, Meropol NJ, Weeks JC, Winn R: Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer 2000, 89(3):561-573.
• [39]Morrow M, White J, Moughan J, Owen J, Pajack T, Sylvester J, Wilson JF, Winchester D: Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma. J Clin Oncol 2001, 19(8):2254-2262.
• [40]Kowdley GC, Merchant N, Richardson JP: Cancer surgery in the elderly. Scientific World J 2012, 2012:303852.
• [41]Medina-Franco H, Abarca-Perez L, Garcia-Alvarez MN, Ulloa-Gomez JL, Romero-Trejo C, Sepulveda-Mendez J: Radioguided occult lesion localization (ROLL) versus wire-guided lumpectomy for non-palpable breast lesions: a randomized prospective evaluation. J Surg Oncol 2008, 97(2):108-111.
• [42]Singletary SE: Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg 2002, 184(5):383-393.
• [43]Krekel NM, Zonderhuis BM, Schreurs HW, Cardozo AM, Rijna H, van der Veen H, Muller S, Poortman P, de Widt L, de Roos WK, Bosch AM, Taets van Amerongen AH, Bergers E, van der Linden MH, de Lange de Klerk ES, Winters HA, Meijer S, van den Tol PM: Ultrasound-guided breast-sparing surgery to improve cosmetic outcomes and quality of life. A prospective multicentre randomised controlled clinical trial comparing ultrasound-guided surgery to traditional palpation-guided surgery (COBALT trial). BMC Surg 2011, 11:8.
• [44]Pleijhuis RG, Graafland M, de Vries J, Bart J, de Jong JS, van Dam GM: Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol 2009, 16(10):2717-2730.
• [45]Yang JD, Lee JW, Kim WW, Jung JH, Park HY: Oncoplastic surgical techniques for personalized breast conserving surgery in breast cancer patient with small to moderate sized breast. J Breast Cancer 2011, 14(4):253-261.
• [46]Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002, 347(16):1227-1232.
• [47]Jeevan R, Cromwell DA, Trivella M, Lawrence G, Kearins O, Pereira J, Sheppard C, Caddy CM, van der Meulen JH: Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics. BMJ 2012, 345:e4505.
• [48]Schwartz GF, Veronesi U, Clough KB, Dixon JM, Fentiman IS, Heywang-Kobrunner SH, Holland R, Hughes KS, Mansel RE, Margolese R, Mendelson EB, Olivotto IA, Palazzo JP, Solin LJ, Consensus Conference Committee: Consensus conference on breast conservation. J Am Coll Surg 2006, 203(2):198-207.
• [49]Silverstein MJ, Skinner KA, Lomis TJ: Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001, 25(6):767-772.
• [50]Fein DA, Fowble BL, Hanlon AL, Hooks MA, Hoffman JP, Sigurdson ER, Jardines LA, Eisenberg BL: Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol 1997, 65(1):34-39.
• [51]Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006, 98(9):599-609.
• [52]Noguchi M, Motomura K, Imoto S, Miyauchi M, Sato K, Iwata H, Ohta M, Kurosumi M, Tsugawa K: A multicenter validation study of sentinel lymph node biopsy by the Japanese Breast Cancer Society. Breast Cancer Res Treat 2000, 63(1):31-40.